An Immunomodulator‐Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine
Advanced Healthcare Materials · 2024-11 · 13 (28)
DOI: 10.1002/adhm.202401635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 25.07.2024. Verfasst von Mengna Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comprehensive Cancer Centre, Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing Univers…. Hauptthemen laut MEDLINE: Cancer Vaccines, Lactococcus lactis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In situ vaccination is an attractive type of cancer immunotherapy, and methods of persistently dispersing immune agonists throughout the entire tumor are crucial for maximizing their therapeutic efficacy. Based on the probiotics usually used for dietary supplements, an immunomodulator‐boosted Lactococcus lactis (IBL) strategy is developed to enhance the effectiveness of in situ vaccination with the immunomodulators. The intratumoral delivery of OX40 agonist and resiquimod‐modified Lactococcus lactis (OR@Lac) facilitates local retention and persistent dispersion of immunomodulators, and dramatically modulates the key components of anti‐tumor immune response. This novel vaccine activated dendritic cells and cytotoxic T lymphocytes in the tumor and tumor‐draining lymph nodes, and ultimately significantly inhibited tumor growth and prolonged the survival rate of tumor‐bearing mice. The combination of OR@Lac and ibrutinib, a myeloid‐derived suppressor cell inhibitor, significantly alleviated or even completely inhibited tumor growth in tumor‐bearing mice. In conclusion, IBL is a promising in situ tumor vaccine approach for clinical application and provides an inspiration for the delivery of other drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comprehensive Cancer Centre, Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210008, China.
- Department of Comprehensive Cancer Centre, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
- Department of Comprehensive Cancer Centre, Nanjing Drum Tower Hospital,Joint Institute of Nanjing Drum Tower Hospital for Life and Health, College of Life Science, Nanjing Normal University, Nanjing, 210008, China.
ORCID-Profile: Fanyan Meng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, M., Shi, T., Tuerhong, S., Li, M., Wang, Q., Lu, C., Zou, L., Zheng, Q., Wang, Y., Du, J., Li, R., Liu, B., & Meng, F. (2024). An Immunomodulator‐Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine. Advanced Healthcare Materials, 13(28). https://doi.org/10.1002/adhm.202401635
Vancouver
Sun M, Shi T, Tuerhong S, Li M, Wang Q, Lu C, et al. An Immunomodulator‐Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine. Advanced Healthcare Materials. 2024;13(28). doi:10.1002/adhm.202401635
BibTeX
@article{Sun2024,
author = {Sun, Mengna and Shi, Tianyu and Tuerhong, Subiyinuer and Li, Mengru and Wang, Qiaoli and Lu, Changchang and Zou, Lu and Zheng, Qinghua and Wang, Yingxin and Du, Juan and Li, Rutian and Liu, Baorui and Meng, Fanyan},
title = {An Immunomodulator‐Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {28},
doi = {10.1002/adhm.202401635}
}
EUVIMED